for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Junshi Biosciences Co Ltd

1877.HK

Latest Trade

45.65HKD

Change

-1.50(-3.18%)

Volume

1,167,200

Today's Range

45.05

 - 

47.75

52 Week Range

36.50

 - 

97.15

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Shanghai Junshi Biosciences Received Clinical Trial Approval For JS012 Injection By NMPA

Nov 19 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::RECEIVED CLINICAL TRIAL APPROVAL FOR JS012 INJECTION BY NMPA.Further company coverage: 688180.SS. ((Reuters.Briefs@thomsonreuters.com;)).

Shanghai Junshi Biosciences Gets Clinical Trial Approval For JS026 Injection

Nov 19 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::GOT CLINICAL TRIAL APPROVAL FOR JS026 INJECTION FROM NMPA.Further company coverage: 688180.SS. ((Reuters.Briefs@thomsonreuters.com;)).

Shanghai Junshi Biosciences Says Toripalimab Granted Orphan-Drug Designation

Nov 15 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::UNIT GOT DESIGNATION LETTER FROM US FDA INDICATING THAT TORIPALIMAB HAS BEEN GRANTED ORPHAN-DRUG DESIGNATION.Further company coverage: 688180.SS. ((Reuters.Briefs@thomsonreuters.com;)).

Shanghai Junshi Biosciences Says Its UBP1213SC Injection Got Clinical Trial Approval

Nov 4 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::UBP1213SC INJECTION RECEIVED CLINICAL TRIAL APPROVAL.GOT CLINICAL TRIAL APPROVAL BY CHINA'S NMPA FOR IND APPLICATION FOR UBP1213SC INJECTION.Further company coverage: 688180.SS. ((Reuters.Briefs@thomsonreuters.com;)).

Shanghai Junshi Biosciences Says Li Cong Re-Designated As Executive Director, Appointed Co-CEO

Nov 2 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::LI CONG RE-DESIGNATED AS AN EXECUTIVE DIRECTOR, APPOINTED AS CO-CEO.Further company coverage: 688180.SS. ((Reuters.Briefs@thomsonreuters.com;)).

Junshi Biosciences, Coherus Announce FDA Acceptance Of BLA Filing For Toripalimab For Treatment Of Nasopharyngeal Carcinoma

Nov 1 (Reuters) - Coherus BioSciences Inc <CHRS.O>::JUNSHI BIOSCIENCES AND COHERUS ANNOUNCE FDA ACCEPTANCE OF BLA FILING FOR TORIPALIMAB FOR TREATMENT OF NASOPHARYNGEAL CARCINOMA.COHERUS BIOSCIENCES - FDA HAS GRANTED PRIORITY REVIEW DESIGNATION FOR TORIPALIMAB BLA AND SET A PDUFA ACTION DATE FOR APRIL 2022.

Shanghai Junshi Biosciences Says JS26 Injection Got Acceptance Notice For Investigational NDA

Oct 28 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::JS026 INJECTION RECEIVED ACCEPTANCE NOTICE FOR INVESTIGATIONAL NEW DRUG APPLICATION FROM NMPA.JS026 INJECTION IS MAINLY USED TO PREVENT AND TREAT COVID-19.Further company coverage: 688180.SS. (Reuters.briefs@thomsonreuters.com).

Shanghai Junshi's Controlling Shareholder Plans To Increase A-Share Holdings

Oct 25 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::SAYS CONTROLLING SHAREHOLDER PLANS TO INCREASE A-SHARE HOLDINGS IN THE COMPANY BY 30-35 MILLION YUAN WITHIN THREE MONTHS FROM NOV 1, 2021.

Shanghai Junshi Biosciences Says Js019 Injection Got Acceptance Notice From NMPA

Oct 21 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::JS019 INJECTION GOT ACCEPTANCE NOTICE FOR INVESTIGATIONAL NEW DRUG APPLICATION FROM NMPA.Further company coverage: 688180.SS. ((reuters.briefs@thomsonreuters.com;)).

Shanghai Junshi Biosciences Says U.S. FDA Expanded Emergency Use Authorization For Etesevimab & Bamlanivimab

Sept 17 (Reuters) - Shanghai Junshi Biosciences Co Ltd <688180.SS>::U.S. FDA EXPANDED EMERGENCY USE AUTHORIZATION FOR ETESEVIMAB AND BAMLANIVIMAB.ETESEVIMAB AND BAMLANIVIMAB ADMINISTERED TOGETHER EXPANDED TO INCLUDE POST-EXPOSURE PROPHYLAXIS FOR COVID-19.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up